The developed pharmaceutical industry is an important guarantee for health, a symbolic industry for modern economy, a strong support for national security, and a strategic position concerning national economy and people's livelihood. Innovative drugs are the embodiment of high-tech comprehensive strength and the core driving force for the development of the pharmaceutical industry.

China's pharmaceutical industry is moving into a golden period of development. It requires a relatively rapid transition to an innovative industry. It requires a professional industry organization, the China Alliance for Innovative Drug Companies (provisional), to unite and mobilize all forces to study and formulate incentives for autonomy. A series of innovative systems have promoted a historic transformation and upgrading to break through the bottleneck of the Chinese pharmaceutical industry from a big pharmaceutical country to a pharmaceutical power.

At present, the key measures to promote the independent innovation of China's pharmaceutical industry to accelerate the development should focus on the following aspects to develop more in-depth discussions:

1. Drug registration approval and intellectual property protection should further encourage and support enterprises to actively invest in the transformation of independent drug innovation drugs, and should make overall plans to give green channels to major product innovation, process innovation, and evaluation innovation.

2. The innovation protection system after the listing of new drugs should be further improved. After the listing of new drugs with superior efficacy on the basis of pharmacological and economic evaluations, they will enter the national health insurance and basic drugs with timely institutional arrangements.

3. Promote the integration of social resources to support the development of drug innovation, and deepen the reform of scientific research management combining production, learning and research with enterprises as the main body.

4. The government will further increase investment in innovative drugs, especially in the critical period of industrial development, focus on the efficiency of fund use, and focus on supporting truly independent innovation.

5. The characteristics of the pharmaceutical industry are high investment, high risk, high returns, and only adequate investment returns can support high levels of R&D and innovation. In the formulation of drug price policies, differentiated management of innovative drugs and generic drugs should be implemented to encourage innovation.